Virtual clinical trials using 3D PET imaging

2019 ◽  
Author(s):  
Paul E. Kinahan ◽  
Darrin Byrd ◽  
Kirsten Wangerin ◽  
Mark Muzi ◽  
Lanell Peterson ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Pet Imaging ◽  
3D Pet

Initial Experience with PET Imaging of Synaptic Density (SV2A) in Alzheimer's Disease: A New Biomarker for Clinical Trials?

2018 ◽  
Vol 26 (3) ◽  
pp. S145-S146 ◽  
Author(s):  
Adam P. Mecca ◽  
Ming-Kai Chen ◽  
Mika Naganawa ◽  
Sjoerd J. Finnema ◽  
Takuya Toyonaga ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Clinical Trials ◽  
Pet Imaging ◽  
Initial Experience ◽  
Synaptic Density

SU-FF-I-151: Effects of Varying Slice Overlap On Image Noise and SNR in 3D PET Imaging

2009 ◽  
Vol 36 (6Part5) ◽  
pp. 2469-2470
Author(s):  
G Chang ◽  
T Chang ◽  
M Khalil ◽  
J Clark ◽  
O Mawlawi
Keyword(s):  
Pet Imaging ◽  
Image Noise ◽  
3D Pet

scholarly journals IC-P-151: TAUIQ : A QUANTITATIVE ALGORITHM TO INCREASE THE POWER OF TAU PET IMAGING IN CLINICAL TRIALS

2019 ◽  
Vol 15 ◽  
pp. P122-P122
Author(s):  
Alex Whittington ◽  
John Seibyl ◽  
Jacob Hesterman ◽  
Roger N. Gunn
Keyword(s):  
Clinical Trials ◽  
Pet Imaging ◽  
Tau Pet ◽  
Tau Pet Imaging

Improving 3D PET imaging by restoration: a phantom study

2005 ◽  
Vol 29 (1) ◽  
pp. 15-19 ◽  
Author(s):  
Karin Knešaurek ◽  
Josef Machac
Keyword(s):  
Pet Imaging ◽  
Phantom Study ◽  
3D Pet

scholarly journals The Landscape of Clinical Trials Evaluating the Theranostic Role of PET Imaging in Oncology: Insights from an Analysis of ClinicalTrials.gov Database

Theranostics ◽  
2017 ◽  
Vol 7 (2) ◽  
pp. 390-399 ◽  
Author(s):  
Yu-Pei Chen ◽  
Jia-Wei Lv ◽  
Xu Liu ◽  
Yuan Zhang ◽  
Ying Guo ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Pet Imaging

scholarly journals Interest and Limits of [18F]ML-10 PET Imaging for Early Detection of Response to Conventional Chemotherapy

2021 ◽  
Vol 11 ◽  
Author(s):  
Elodie Jouberton ◽  
Sébastien Schmitt ◽  
Aurélie Maisonial-Besset ◽  
Emmanuel Chautard ◽  
Frédérique Penault-Llorca ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Cell Death ◽  
Image Analysis ◽  
Early Detection ◽  
Pet Imaging ◽  
Therapeutic Response ◽  
Conventional Chemotherapy ◽  
Predictive Tool ◽  
Good Ability ◽  
Specificity And Sensitivity

One of the current challenges in oncology is to develop imaging tools to early detect the response to conventional chemotherapy and adjust treatment strategies when necessary. Several studies evaluating PET imaging with 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG) as a predictive tool of therapeutic response highlighted its insufficient specificity and sensitivity. The [18F]FDG uptake reflects only tumor metabolic activity and not treatment-induced cell death, which seems to be relevant for therapeutic evaluation. Therefore, to evaluate this parameter in vivo, several cell death radiotracers have been developed in the last years. However, few of them have reached the clinical trials. This systematic review focuses on the use of [18F]ML-10 (2-(5-[18F]fluoropentyl)-2-methylmalonic acid) as radiotracer of apoptosis and especially as a measure of tumor response to treatment. A comprehensive literature review concerning the preclinical and clinical investigations conducted with [18F]ML-10 was performed. The abilities and applications of this radiotracer as well as its clinical relevance and limitations were discussed. Most studies highlighted a good ability of the radiotracer to target apoptotic cells. However, the increase in apoptosis during treatment did not correlate with the radiotracer tumoral uptake, even using more advanced image analysis (voxel-based analysis). [18F]ML-10 PET imaging does not meet current clinical expectations for early detection of the therapeutic response to conventional chemotherapy. This review has pointed out the challenges of applying various apoptosis imaging strategies in clinical trials, the current methodologies available for image analysis and the future of molecular imaging to assess this therapeutic response.

Design of an Architecture for Real-Time 3D PET Imaging

1998 ◽  
Vol 4 (4) ◽  
pp. 255-262 ◽  
Author(s):  
Eugenio Di Sciascio ◽  
Anna R. Manni ◽  
Riccardo Guzzardi
Keyword(s):  
Real Time ◽  
Pet Imaging ◽  
3D Pet

scholarly journals TMIC-39. DEVELOPMENT OF CD11b TRACER FOR THE IMMUNE PET IMAGING IN GLIOBLASTOMA MODEL - COULD BE A GAME CHANGER FOR IMMUNOTHERAPY APPROACHES

2019 ◽  
Vol 21 (Supplement_6) ◽  
pp. vi256-vi256
Author(s):  
Shubhanchi Nigam ◽  
Lauren McCarl ◽  
Rajeev Kumar ◽  
Carolyn Anderson ◽  
Barry Edwards ◽  
...  
Keyword(s):  
Flow Cytometry ◽  
Clinical Trials ◽  
Pet Imaging ◽  
Specific Activity ◽  
Malignant Gliomas ◽  
Myeloid Cells ◽  
Cd11b Expression ◽  
Left Brain ◽  
Right Brain ◽  
The Right

Abstract Glioblastoma is a lethal brain tumor, heavily infiltrated by tumor-associated myeloid cells (TAMCs). As up to 30% of a glioma cellular mass may be attributed to immunosuppressive myeloid cells, including myeloid-derived suppressor cells (MDSCs) and tumor-associated macrophages (TAMs). TAMCs impede natural and immunotherapy-driven anti-tumor responses, they are a high-priority and promising therapeutic target currently being evaluated in clinical trials. Multiple preclinical and clinical trials have attempted to target these cells, however monitoring of biologic responses to therapy remains a challenge. Quantifying real time status of MDSCs and TAMs at the tumor site using non-invasive immunoPET could improve therapeutic response and allow for better patient stratification and monitoring of targeted treatment responses. TAMCs highly expressed the cell surface marker, integrin CD11b (Mac-1, αMβ2) and may be a highly effective imaging target for immunoPET strategies. The human/mouse cross-reactive anti-CD11b antibody (clone M1/70) was radiolabeled with 89Zr for PET imaging. PET/CT imaging, with or without a blocking dose of anti-CD11b Ab, was performed in mice bearing established orthotopic syngeneic GL261 gliomas. Flow cytometry and histology in tissues collected from post-imaging biodistribution validated targeting of CD11b+ MDSCs and TAMs. There was significant Zr-89-anti-CD11b Ab uptake in the tumor ipsilateral right brain (SUVmean = 2.6 ± 0.24) compared to contralateral left brain (SUVmean = 0.6 ± 0.11). Blocking with 10-fold lower specific activity 89Zr-anti-CD11b Ab reduced the SUV in right brain with (SUVmean = 0.11 ± 0.06). Immune rich organs spleen and lymph nodes showed high uptake. These results correlated with biodistribution analysis. CD11b expression in the right and left brain were validated using flow cytometry, H&E and IHC, showing high CD11b expression in the right brain. Imaging TAMs and MDSCs with 89Zr-labeled anti-CD11b Ab targeting was validated in a mouse model of malignant gliomas, demonstrating the feasibility of monitoring immune response during immunotherapy.

Sign in / Sign up

Export Citation Format

Share Document